Zimmer Biomet Holdings, Inc.
New York Stock ExchangeCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Ivan Tornos
- Full Time Employees
- 17,000
- Sector
- Healthcare
- Industry
- Medical - Devices
- Address
- 345 East Main Street Warsaw IN United States of America 46580
- IPO Date
- Jul 25, 2001
- CIK
- 0001136869
- Website
- zimmerbiomet.com
- Similar Companies
- Business
- Zimmer Biomet Holdings, Inc. designs, manufactures, and markets orthopedic reconstructive products; sports medicine, biologics, and extremities technologies; surgical and precision instruments; dental implants; and bone cement products worldwide. Founded in 1927 and headquartered in Warsaw, Indiana, the company operates globally with approximately 17,000 employees across 31 offices, serving healthcare professionals and patients through innovative implants, digital technologies, robotics, and analytics that span the patient journey from pre- to post-operative care. Core offerings include the ROSA Robotics platform for imageless knee and hip procedures; knee systems such as Persona and Oxford; hip solutions like Avenir Complete and Arcos Modular Revision; foot and ankle products including A.L.P.S. plating systems and recent Gorilla Pilon Fusion Plating and Phantom TTC Trauma Nail; trauma fixation devices; sports medicine technologies like BioCUE and AperFix; dental reconstructive implants; and integrated digital tools such as mymobility platform and AI-driven navigation. Recent developments encompass the October 2025 completion of the Monogram Technologies acquisition, enhancing semi- and fully autonomous robotics capabilities; the Paragon 28 acquisition bolstering foot and ankle and SET business growth; FDA clearance in November 2025 for ROSA Knee with OptimiZe; launches of the Magnificent Seven product suite; and plans for smart implants, next-generation ROSA robotics in 2026, and 20 new SCT products, driving projected 3.5-4.5% revenue growth in 2025 amid U.S. commercial specialization and ASC channel expansion.
Zimmer Biomet Q2 Earnings Call Highlights
Here's Why Zimmer Biomet (ZBH) is a Strong Momentum Stock
Zimmer Biomet Q2 Earnings Call Highlights
Here's Why Zimmer Biomet (ZBH) is a Strong Value Stock
Zimmer Biomet Holdings, Inc. (ZBH) Q2 2026 Earnings Call Transcript
ZBH's Q2 Earnings Beat, '26 View Raised, Stock Up in Pre-Market
Zimmer (ZBH) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
Zimmer Biomet (ZBH) Q2 Earnings and Revenues Beat Estimates
Zimmer Biomet Announces Second Quarter 2026 Financial Results
Can These 3 MedTech Stocks Hit Targets This Earnings Season?
Zimmer Biomet Set to Report Q2 Earnings: What's in the Cards?
Here Are Tuesday’s Top Wall Street Analyst Research Calls: Boston Scientific, Clorox, CrowdStrike, Exxon Mobil, Honeywell International, Intuit, Intuitive Surgical, Levi Strauss, and More
Gabelli Funds LLC Boosts Stock Holdings in Zimmer Biomet Holdings, Inc. $ZBH
ABN Amro Investment Solutions Sells 15,516 Shares of Zimmer Biomet Holdings, Inc. $ZBH
Why Zimmer Biomet (ZBH) is a Top Value Stock for the Long-Term
D.A. Davidson & CO. Has $2.67 Million Stake in Zimmer Biomet Holdings, Inc. $ZBH
Zimmer Biomet Names Chintan Desai President of Asia Pacific Region
Zimmer Biomet Announces Webcast and Conference Call of Second Quarter 2026 Financial Results
Is Zimmer Biomet Stock the Right Pick for Your Portfolio Now?
Zimmer Biomet (ZBH) is a Top-Ranked Value Stock: Should You Buy?